510(k) Report

510(k) · Cleared

Cleared

ARCHITECT iGentamicin

K243500510(k) SpecialCleared Jul 9, 2025239-day reviewClass II21 CFR 862.3450

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Abbott Laboratories · LCD Enzyme Immunoassay, Gentamicin

Cleared on Jul 9, 2025 as substantially equivalent to K102699 (Abbott Laboratories, 2011) after a 239-day review. Its family tree reaches back 2 generations to 1994.

Decided
Jul 9, 2025
Review
239 days
Class
Class II
Product code
LCD
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K935376 (1994). No later device cites it as a predicate yet.

  1. Root · 2 generations backK935376 Axsym GentamicinAbbott Mfg., Inc. · 1994 · Recalled
  2. 1 generation backK102699 Architect Igentamicin Reagents; Architect Igentamicin CalibratorsAbbott Laboratories · 2011 · Recalled
  3. This deviceK243500 ARCHITECT iGentamicinAbbott Laboratories · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K935376Axsym GentamicinAbbott Mfg., Inc.19941
−1K102699Architect Igentamicin Reagents; Architect Igentamicin CalibratorsAbbott Laboratories20111
0 (this device)K243500ARCHITECT iGentamicinAbbott Laboratories2025—
FIG. 1 — Lineage of K243500, 1994–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LCD? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K102699Architect Igentamicin Reagents; Architect Igentamicin Calibrators
Summary page 6
…Classification Name: Gentamicin test system Governing Regulation: 862.3450 Product Code: LCD IV. Predicate Device ARCHITECT iGentamicin (k102699) V. Intended Use of the Device The ARCHITECT iGentamicin assay is an in vitro chemiluminescent microparticle immunoassa…
Abbott Laboratories20111

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 31 years and passes through 2 companies; a new generation was cleared every 16.8 years on median.
  • 2 of the 2 ancestors have a recall of any class.

How does its category compare?

All LCD devices

LCD Enzyme Immunoassay, Gentamicin: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · LCD

1in 2025

2011: 12025: 1
2007high 1 (2011) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LCD

Too few LCD 510(k)s in any year since 2007 to give a median.

Recalls per year · LCD

1in 2010

2007: 12009: 42010: 1
2007high 4 (2009) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LCD

2in 2024

2009: 32010: 42011: 32012: 192013: 162014: 32015: 22016: 82017: 12018: 22019: 12020: 12024: 2
2007high 19 (2012) · low 0 (2007)2025

MAUDE reports naming product code LCD, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—10
20080—00
20090—43
20100—14
20111—03
20120—019
20130—016
20140—03
20150—02
20160—08
20170—01
20180—02
20190—01
20200—01
20210—00
20220—00
20230—00
20240—02
20251—00
20260—0—

What is it indicated for?

The ARCHITECT iGentamicin assay is an in vitro chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of gentamicin, an antibiotic drug, in human serum or plasma on the ARCHITECT iSystem with STAT protocol capability. The measurements obtained are used in the diagnosis and treatment of gentamicin overdose and in monitoring levels of gentamicin to help ensure appropriate therapy.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K243500: ARCHITECT iGentamicin.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K243500

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026